Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
RESEARCH TOOLSreports
Intra-Cellular Therapies (ITCI) Ownership - Who Owns Intra-Cellular Therapies?
842 Followers
Intra-Cellular Therapies (ITCI) Ownership Overview
31.90% Insiders
33.73% Mutual Funds
13.75% Other Institutional Investors
20.62% Public Companies and Individual Investors
The ownership structure of Intra-Cellular Therapies (ITCI) stock is a mix of institutional, retail and individual investors. Approximately 47.48% of the company’s stock is owned by Institutional Investors, 31.90% is owned by Insiders and 20.62% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Jun 25, 2024 | Rory Riggs Director | Sold | $337193 |
| Feb 28, 2024 | Robert Van Nostrand Director | Sold | $1458650 |
| Feb 27, 2024 | Joel Marcus Director | Sold | $1808253 |
| Nov 08, 2023 | Mark Neumann Evp & Cco | Sold | $2357990 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Mar 31, 2024 | Bought | $149956 | |
| Mar 31, 2024 | Bought | $253272 | |
| Mar 31, 2024 | Bought | $1183804 | |
| Mar 31, 2024 | Bought | $1557000 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 9,298,069 | Institution | 8.81% | 632,175,711 | |
| 7,922,822 | Institution | 7.50% | 538,672,668 | |
| 5,736,643 | Insider | 5.43% | 390,034,358 | |
| 4,645,672 | Institution | 4.40% | 315,859,239 | |
| 3,638,389 | Insider | 3.45% | 247,374,068 | |
| 3,596,205 | Insider | 3.41% | 244,505,978 | |
| 3,596,205 | Insider | 3.41% | 244,505,978 | |
| 2,959,682 | Institution | 2.80% | 201,228,779 | |
| 2,230,765 | Institution | 2.11% | 151,669,712 | |
| 1,193,732 | Institution | 1.13% | 81,161,839 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 7,922,822 | Institution | 7.50% | 538,672,668 | |
| 4,645,672 | Institution | 4.40% | 315,859,239 | |
| 2,230,765 | Institution | 2.11% | 151,669,712 | |
| 1,062,355 | Institution | 1.01% | 72,229,516 | |
| 1,055,732 | Institution | 1.00% | 71,779,219 | |
| 1,048,130 | Institution | 0.99% | 71,262,359 | |
| 954,007 | Institution | 0.90% | 64,862,936 | |
| 941,088 | Institution | 0.89% | 63,984,573 | |
| 921,771 | Institution | 0.87% | 62,671,210 | |
| 910,528 | Institution | 0.86% | 61,906,799 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,123,223 | Institution | 2.96% | 210,005,515 | |
| 2,510,131 | Institution | 2.38% | 168,781,208 | |
| 1,448,042 | Institution | 1.37% | 97,366,344 | |
| 1,427,355 | Institution | 1.35% | 95,975,350 | |
| 731,745 | Institution | 0.69% | 49,751,343 | |
| 558,977 | Institution | 0.53% | 38,004,846 | |
| 534,463 | Institution | 0.51% | 36,338,139 | |
| 460,873 | Institution | 0.44% | 31,565,192 | |
| 376,208 | Institution | 0.36% | 25,296,226 | |
| 371,193 | Institution | 0.35% | 25,237,412 |
FAQ
Who Owns Intra-Cellular Therapies (ITCI)?
According to the latest TipRanks data, approximately 13.75% of the company's stock is held by institutional investors, 31.90% is held by insiders, and 20.62% is held by retail investors.
What percentage of Intra-Cellular Therapies (ITCI) stock is held by institutional investors?
According to the latest TipRanks data, approximately 13.75% of Intra-Cellular Therapies (ITCI) stock is held by institutional investors.
What percentage of Intra-Cellular Therapies (ITCI) stock is held by retail investors?
According to the latest TipRanks data, approximately 20.62% of Intra-Cellular Therapies (ITCI) stock is held by retail investors.
Who owns the most shares of Intra-Cellular Therapies (ITCI)?
Vanguard owns the most shares of Intra-Cellular Therapies (ITCI).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.